Latest news with #Prolia
Telegraph
4 days ago
- Business
- Telegraph
Forget Ozempic and Mounjaro, this firm is on the edge of a weight-loss breakthrough
Questor is The Telegraph's stock-picking column, helping you decode the markets and offering insights on where to invest. This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough action on drug pricing and tariffs have fuelled nervousness, while recently agreed cuts to Medicaid in the 'big beautiful bill' are also causing concern. But medicine will always be a priority for the sick, and innovations from the pharmaceutical industry are vital for creating healthier societies as populations age. Biotech giant Amgen looks particularly well placed to weather current uncertainties and prosper from the long-term prospects of its industry. A first-class dividend record, which includes increased payouts in each of the last 13 years, is testament to the resilience of the business. Key to this is that unlike many rivals, no one product dominates Amgen's $33.4bn (£24.7bn) of sales. In fact, the company boasts 14 blockbuster drugs with over $1bn sales each. This product diversity means that while its biggest selling treatment – an osteoporosis drug called Prolia that generated $4.4bn revenues last year – is expected to see rapid declines following its loss of patent protection in February, the company's top line is forecast to grow. The drugs Amgen sells cover a number of different areas, including cancer, cardiovascular disease, osteoporosis and rare diseases. Recent trading has been strong, too, with 21 drugs reporting record sales last year and 14 reporting double-digit growth. Amgen is experiencing particularly strong growth from cholesterol drug Repatha, which is forecast to net $2.8bn this year, and osteoporosis treatment Evenity, both of which target underserved patient groups. Sales are also soaring for cancer drug Blincyto. In terms of the problems posed by Trump, Amgen looks well placed. Tariffs should not be a major issue given it mostly manufactures in the US, where it is currently increasing capacity. Having just opened a new facility in Ohio, it plans to plough another $900m into growth in the state and a further $1bn is being spent building in North Carolina. Much of this spending is aimed at increasing production of biosimilars, which are lower cost versions of existing drugs that have lost patent protection. This focus should help position the group to deal with the US government's drug-pricing agenda because biosimilars help lower healthcare costs. Amgen has said Medicaid cuts could have a material adverse impact on some drug sales, however, the cuts passed in the big beautiful bill last week were scaled back in order to get it approved. Reassurance about prospects can also be taken from the number of top fund managers backing the stock – all among the best-performing 3pc globally according to financial publisher Citywire. A total of 14 of these individuals back the shares. The level of smart-money backing has won Amgen a place in Citywire's Global Elite Companies index, which is home to the 76 very best ideas from among the c.6,000 stocks held across the portfolios of the top managers Citywire tracks. For these backers, the potential of Amgen's drug development is a key part of its attraction. Investors have been particularly excited about a long-lasting obesity drug Amgen has begun late-stage phase III trials for, called MariTide. It produces similar levels of weight-loss as Wegovy and Zepbound, which are multibillion-dollar treatments made by Novo Nordisk and Eli Lilly respectively, but MariTide only needs to be injected once a month or less, compared with weekly for the existing drugs. While the potential is exciting, the market reacted negatively to recent news of high levels of nausea during early use. Amgen reckons it can address this by starting patients on lower doses. Better trial news has recently come from cancer treatments, specifically a stomach cancer drug called Bemarituzumab. Amgen is also looking to extend the uses of some of its existing blockbuster medicines. The company put a record $6bn into research and development last year pursuing new opportunities, which represented more than 18pc of sales and a 25pc increase on 2023. While Amgen's margins have nudged down over recent years, it is nevertheless highly profitable. It reported 46.9pc underlying operating margins last year. Meanwhile, solid earnings per share growth is predicted over the next two years of just over 4pc on an annualised basis. That looks an attractive package with the shares priced at 14 times forecast earnings and yielding 3.4pc, especially once the potential for positive surprises from the busy development pipeline is factored in. British buyers of the shares need to fill out the correct paperwork to minimise withholding taxes and check for any extra dealing costs with brokers. Questor says: buy Ticker: NYSE:AMGN
Korea Herald
08-07-2025
- Business
- Korea Herald
Celltrion debuts denosumab biosimilars in US
South Korean biopharmaceutical firm Celltrion said Tuesday that it had released its denosumab biosimilars, Stoboclo and Osenvelt, in the US market, which is valued at approximately 9 trillion won ($6.5 billion). The biosimilars are approved for all indications of the original drugs, Prolia and Xgeva, after Celltrion secured full-label FDA approval in March and finalized a patent settlement with the original manufacturer. The products launched at a wholesale acquisition cost about 5 percent lower than the originals and will be distributed directly through Celltrion's US subsidiary. To support its market entry, Celltrion signed a supply agreement with a major US hospital group, ensuring product availability from the launch date. The company aims to rapidly expand its presence in the US 'open market,' which accounts for 30 percent of the denosumab segment and is less influenced by pharmacy benefit managers. The bio giant anticipates revenue growth for the release, as the original drugs, Prolia and Xgeva, generated a combined global revenue of approximately 9.2 trillion won in 2024 worldwide. 'Stoboclo-Osenvelt will expand treatment options for US patients while enhancing accessibility,' said Thomas Nusbickel, chief commercial officer of Celltrion USA. 'We're confident in our ability to scale prescriptions and secure share through both open market and PBM channels.'
Yahoo
29-05-2025
- Business
- Yahoo
Denosumab Market Report 2025-2029 & 2034: Strategic Collaborations and Digital Health Pave the Way for Innovations, First-Line Treatment Boyoubei Gains Traction
Explore the booming denosumab market, projected to reach $5.59 billion by 2029 with a CAGR of 10.9%. Key growth drivers include osteoporosis prevalence, innovative treatments, and strategic partnerships. Major players like Amgen and Boan Biotech are at the forefront, with North America leading and Asia-Pacific emerging rapidly. Denosumab Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Denosumab Market Report 2025" has been added to offering. The denosumab market has experienced robust growth, increasing from $3.27 billion in 2024 to an expected $3.7 billion in 2025, registering a CAGR of 13.1%. This growth has been supported by clinical trials, research advancements, FDA approvals, an increased focus on bone health, and strategic partnerships. As the demand continues, projections indicate the market will reach $5.59 billion by 2029, with a CAGR of 10.9% for the forecast period. This anticipated growth is linked to a rising incidence of bone metastases and advancements in both cancer therapies and osteoporosis awareness. Recent studies, including one from the National Center for Biotechnology Information, highlight the prevalence of osteoporosis, with figures such as a 12.7% prevalence in women diagnosed by physicians in Canada. These statistics underscore the expanding need for effective treatments like denosumab, which targets bone resorption, thereby aiding in reducing fracture risks. Key market players are enhancing their offerings, as seen with Boan Biotech's November 2022 introduction of Boyoubei, a denosumab biosimilar. Securing approval from China's National Medical Products Administration, this biosimilar stands unique as the first to receive global marketing approval. Strategies include penetration into the U.S. and European markets with hopes to impact osteoporosis treatment guidelines. Strategic collaborations are shaping the market. For instance, in June 2022, Organon entered into a partnership with Henlius to commercialize biosimilar candidates referencing Prolia and Xgeva (Denosumab). This alliance emphasizes Organon's commitment to affordable healthcare, particularly focusing on women's health. Major companies in this market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, and Amgen Inc., among others. With North America leading the market in 2024, Asia-Pacific is expected to be the fastest-growing region due to rising healthcare advancements and awareness. The denosumab market includes sales of calcium and vitamin D supplements, with values representing factory-gate sales, encompassing the goods sold by manufacturers to various entities. The market also covers comprehensive reports addressing market size, regional shares, and detailed segments, providing a holistic perspective of industry trends. This market, valued in USD unless specified, includes revenues from direct sales, highlighting its importance across multiple geographies, including Asia-Pacific, Western and Eastern Europe, North America, and beyond. Denosumab, as a monoclonal antibody, plays a critical role in treating bone-related conditions, specifically osteoporosis and bone metastases, revealing its ongoing importance in the healthcare landscape. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $3.7 Billion Forecasted Market Value (USD) by 2029 $5.59 Billion Compound Annual Growth Rate 10.9% Regions Covered Global Scope: Markets Covered: By Drug Classification:Prolia, Xgeva, Others By Type:60 mg, 120 mg By End-Users:Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers Companies Featured Johnson & Johnson F. Hoffmann-La Roche Ltd. Novartis International AG Sanofi SA GlaxoSmithKline plc Eli Lilly and Company Amgen Inc. Asahi Kasei Corporation Teva Pharmaceutical Industries Ltd. Astellas Pharma Inc. Daiichi Sankyo Company, Limited Mylan N.V. Sandoz International GmbH Daiichi Sankyo Company Limited Aurobindo Pharma Limited Cipla Limited Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals PLC Celltrion Inc. Amneal Pharmaceuticals Inc Cadila Healthcare Limited Lupin Limited Biocon Limited Torrent Pharmaceuticals Ltd. Jubilant Life Sciences Limited Ajanta Pharma Limited For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Denosumab Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
Denosumab Market Report 2025-2029 & 2034: Strategic Collaborations and Digital Health Pave the Way for Innovations, First-Line Treatment Boyoubei Gains Traction
Explore the booming denosumab market, projected to reach $5.59 billion by 2029 with a CAGR of 10.9%. Key growth drivers include osteoporosis prevalence, innovative treatments, and strategic partnerships. Major players like Amgen and Boan Biotech are at the forefront, with North America leading and Asia-Pacific emerging rapidly. Denosumab Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Denosumab Market Report 2025" has been added to offering. The denosumab market has experienced robust growth, increasing from $3.27 billion in 2024 to an expected $3.7 billion in 2025, registering a CAGR of 13.1%. This growth has been supported by clinical trials, research advancements, FDA approvals, an increased focus on bone health, and strategic partnerships. As the demand continues, projections indicate the market will reach $5.59 billion by 2029, with a CAGR of 10.9% for the forecast period. This anticipated growth is linked to a rising incidence of bone metastases and advancements in both cancer therapies and osteoporosis awareness. Recent studies, including one from the National Center for Biotechnology Information, highlight the prevalence of osteoporosis, with figures such as a 12.7% prevalence in women diagnosed by physicians in Canada. These statistics underscore the expanding need for effective treatments like denosumab, which targets bone resorption, thereby aiding in reducing fracture risks. Key market players are enhancing their offerings, as seen with Boan Biotech's November 2022 introduction of Boyoubei, a denosumab biosimilar. Securing approval from China's National Medical Products Administration, this biosimilar stands unique as the first to receive global marketing approval. Strategies include penetration into the U.S. and European markets with hopes to impact osteoporosis treatment guidelines. Strategic collaborations are shaping the market. For instance, in June 2022, Organon entered into a partnership with Henlius to commercialize biosimilar candidates referencing Prolia and Xgeva (Denosumab). This alliance emphasizes Organon's commitment to affordable healthcare, particularly focusing on women's health. Major companies in this market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, and Amgen Inc., among others. With North America leading the market in 2024, Asia-Pacific is expected to be the fastest-growing region due to rising healthcare advancements and awareness. The denosumab market includes sales of calcium and vitamin D supplements, with values representing factory-gate sales, encompassing the goods sold by manufacturers to various entities. The market also covers comprehensive reports addressing market size, regional shares, and detailed segments, providing a holistic perspective of industry trends. This market, valued in USD unless specified, includes revenues from direct sales, highlighting its importance across multiple geographies, including Asia-Pacific, Western and Eastern Europe, North America, and beyond. Denosumab, as a monoclonal antibody, plays a critical role in treating bone-related conditions, specifically osteoporosis and bone metastases, revealing its ongoing importance in the healthcare landscape. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $3.7 Billion Forecasted Market Value (USD) by 2029 $5.59 Billion Compound Annual Growth Rate 10.9% Regions Covered Global Scope: Markets Covered: By Drug Classification:Prolia, Xgeva, Others By Type:60 mg, 120 mg By End-Users:Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers Companies Featured Johnson & Johnson F. Hoffmann-La Roche Ltd. Novartis International AG Sanofi SA GlaxoSmithKline plc Eli Lilly and Company Amgen Inc. Asahi Kasei Corporation Teva Pharmaceutical Industries Ltd. Astellas Pharma Inc. Daiichi Sankyo Company, Limited Mylan N.V. Sandoz International GmbH Daiichi Sankyo Company Limited Aurobindo Pharma Limited Cipla Limited Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals PLC Celltrion Inc. Amneal Pharmaceuticals Inc Cadila Healthcare Limited Lupin Limited Biocon Limited Torrent Pharmaceuticals Ltd. Jubilant Life Sciences Limited Ajanta Pharma Limited For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Denosumab Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Better Weight Loss Stock: Amgen or Viking Therapeutics?
Amgen's weight loss candidate reported mixed phase 2 data, but the company has other weapons. Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only promising candidate. Deciding between these two stocks might come down to each investor's style, priorities, and risk tolerance. 10 stocks we like better than Amgen › Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two leaders in this area, Eli Lilly and Novo Nordisk. However, several other companies seem to have somewhat promising prospects in this field. This group includes Amgen (NASDAQ: AMGN) and Viking Therapeutics (NASDAQ: VKTX), two drugmakers that have produced phase 2 clinical trial data for their leading weight management candidates. Despite these positive clinical developments, Amgen and Viking Therapeutics have performed poorly on the stock market in the past 12 months, though progress in this area might eventually help them bounce back. But which of these two biotechs should investors trying to profit from the rapid spending on anti-obesity medicines put their money in? Amgen's leading weight loss candidate is called MariTide. In November, the biotech reported that in a phase 2 study, the medicine led to an average weight loss of about 20% in overweight or obese patients after 52 weeks, with no weight loss plateau observed. Importantly, MariTide is administered subcutaneously once a month -- the current weight management leaders are taken once weekly. A less frequent dosing could appeal to many patients. The market expected greater weight loss in this study. That's why Amgen's shares fell after it released its phase 2 results. However, the company's data still makes it somewhat likely that it will go on to carve out a solid niche in the rapidly growing weight loss area, although it won't dethrone the leaders. Further, Amgen's prospects go well beyond its work in the anti-obesity market. The company's deep lineup allows it to generate consistent revenue and profits. In the first quarter, Amgen's sales increased by 9% year over year to $8.1 billion, while its adjusted earnings per share came in at $4.90, 24% higher than the year-ago period. Amgen has several growth drivers. Tezspire, an asthma medicine, is performing well, as is Prolia, a treatment for osteoporosis (a bone disease) in postmenopausal women. Amgen also has a deep pipeline of investigational products besides MariTide that will eventually lead to brand-new medicines. Lastly, it is an excellent dividend stock. It offers a forward yield of 3.5% -- compared to the S&P 500 index's average of 1.3% -- and has increased its payouts by 201.3% in the past 10 years. Amgen could generate strong returns over the long run even if MariTide doesn't pan out. Viking Therapeutics is a clinical-stage biotech. The company's VK2735, its weight management candidate, looks promising. Last year, it reported that at the highest dose, the drug led to a placebo-adjusted mean weight loss of 13.1% (or 14.7% from baseline) after a mere 13 weeks. VK2735 is in the same class of drugs as Eli Lilly's Zepbound. It mimics the action of two gut hormones: GLP-1 and GIP. That doesn't guarantee that it will achieve the same kind of success, but so far, the data looks highly encouraging. Viking Therapeutics has other candidates. The company's VK2809 targets metabolic dysfunction-associated steatohepatitis. It delivered solid phase 2 results last year. Viking Therapeutics is also developing an oral formulation of VK2735 that is currently in mid-stage studies, while VK0214 is an investigational treatment for a rare, nervous system disorder called X-linked adrenoleukodystrophy. There is no approved treatment for the disease yet. Viking Therapeutics carries above-average risk, as do all biotech companies without a single product on the market. But if VK2735 aces phase 3 results and earns approval -- and Viking's other candidates pan out as well -- the stock could deliver substantial returns. Amgen is a well-established company that generates consistent financial results. It also pays a dividend. It is a far better option for low-risk, income-seeking investors. There is no contest there. However, Viking Therapeutics has far more upside potential. If the smaller biotech can deliver solid pipeline and regulatory progress in the next few years, its shares will likely skyrocket. Note that the company also has significant potential drawbacks. It could be more appealing for investors with a higher tolerance for volatility. Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $644,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $807,814!* Now, it's worth noting Stock Advisor's total average return is 962% — a market-crushing outperformance compared to 169% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Better Weight Loss Stock: Amgen or Viking Therapeutics? was originally published by The Motley Fool
